Difference between revisions of "LGD4033 Half Life"

Latest revision as of 21:09, 15 May 2024

LGD-4033 is a fairly new Selective Androgen Receptor Modulator (SARM) that was discovered by Ligand Pharmaceuticals. It is an oral steroid that can be taken in low doses and is liver-safe, unlike most oral steroids. It is reported to bind to the androgen receptor with extremely high affinity and selectivity, and then exert anabolic effects in muscle tissue. lgd has been shown to increase lean mass in phase 1 clinical trials by 2.67 pounds, which makes it more potent than many well-known testosterone analogs.

LGD 4033 is a very popular SARM amongst both medical and recreational users. It is a very anabolic agent that has been proven to increase muscle mass, but also increases bone density and decrease body fat. It is not as androgenic as traditional testosterone, which makes it a good choice for women who are afraid of virilization. In addition, it has been shown to increase skeletal muscle accretion and vascularization, while inhibiting unwanted tissue growth such as the prostate or breasts.

In a study using an animal model for hypogonadism, LGD-4033 was found to exhibit desirable in vivo outcomes such as increasing muscle mass and bone density. It is important to note that this 3-week study was not designed to demonstrate maximal effects, and therefore larger and longer studies will be needed to access efficacy.

It was also demonstrated in the same rat model that LGD-4033 has superiority to the current anabolic androgenic steroid GTx-024, better known as Ostarine or Enobosarm. This was due to the fact that LGD-4033 was able to exhibit anabolic effects at lower doses, and without the significant androgenic side effects seen with other androgens.

A human metabolism and excretion study of LGD-4033 has been published, revealing two trihydroxylated metabolites in urine. These metabolites have been identified as the main active molecule, and are also present in plasma. Bloodstream concentration of LGD-4033 exhibited an accumulative effect, and levels tripled by day 21 compared to day 1. The elimination half life for LGD-4033 is 24-36 hours, so it would not be recommended to split the dosage throughout the day.

LGD-4033 does not aromatize, but some users report that it suppresses natural hormone production and may cause a moderate testosterone reduction after discontinuation. For this reason, some users recommend a light PCT with Clomid or Nolvadex after each cycle. Nevertheless, many users have no need for PCT and continue to use LGD-4033 on its own. Swolverine does not support the use of illegal or nefarious substances or compounds, and recommends users consult with a physician prior to commencing any supplemental anabolic/androgenic drug regimen.